SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending after reporting substantial revenue growth and positive adjusted EBITDA, coupled with increased capacity guidance and the strategic acquisition of AI agentic search company Tavily. The community is actively debating whether these strong operational metrics and strategic moves outweigh a perceived earnings miss, positioning NBIS as a highly discussed AI infrastructure play amid intense sector demand.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as its oral obesity drug VK2735 received FDA clearance to skip a trial phase and advance directly into Phase 3, significantly accelerating its development timeline in the competitive GLP-1 market. This strategic acceleration, coupled with promising data from its injectable program and recent regulatory actions against compounded alternatives, has fueled community discussions about potential partnerships or a significant short squeeze, despite recent mixed financial results.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc. is trending after reporting record quarterly and annual results, marking its first profitable fiscal year, and highlighting AI agent traffic as a significant tailwind for its edge computing services. The community is actively discussing the company's accelerating growth, improving profitability, and perceived undervaluation relative to peers, with many seeing a significant rerating ahead for the edge computing provider.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending following the U.S. FDA approval of its Optune Pax, a Tumor Treating Fields therapy for locally advanced pancreatic cancer, hailed as the first new treatment in three decades with improved patient outcomes. The community is actively debating significant upside potential from this groundbreaking news, while some caution about previous stock volatility and potential commercial challenges, despite promising survival and pain progression data from trials.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical ($DRTS) is trending amid high anticipation for imminent Japan PMDA approval and recent positive news regarding a second successfully treated GBM patient. The community is increasingly bullish, citing growing institutional accumulation and the transformative potential of its Alpha DaRT technology, which demonstrates broad efficacy across solid tumors.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is trending following an unexpected adjusted earnings and revenue beat, defying earlier market pessimism and driving a significant rally. Community sentiment highlights the stock's perceived undervaluation, ongoing share buybacks, and signs of stabilization in its HeyDude brand as key drivers, despite broader sector headwinds.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is surging after a major short-seller retracted a damaging report and issued an apology, driving community discussion around the stock's strong AI-driven ad-tech fundamentals and an anticipated rally ahead of its upcoming earnings.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid a recent workforce reduction and a legal ruling allowing a key patent lawsuit to proceed, intensifying community speculation. Investors are sharply divided between frustration over management's perceived missteps and strong hopes for an imminent acquisition, particularly by Nestle, given the underlying value of its microbiome platform and lead candidate SER-155.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after its Q4 earnings report highlighted the operational "Eagle Line" pilot production and B-sample shipments to multiple OEMs, sparking intense debate. Bulls see this as a pivotal move towards commercialization and a licensing model, while bears remain critical of the continued lack of concrete revenue, profits, and specific customer commitments, questioning its valuation in the competitive solid-state battery sector.

Iron Mountain, Inc. engages in the provision of storage and information management solutions. It operates through the following business segments: Global Records & Information Management Business, Global Data Center Business and Corporate & Other Business. The Global Records & Information Management Business segment offers comprehensive solutions for storing, managing, digitizing, and securely disposing of records and information worldwide. The Global Data Center Business segment provides data center facilities to protect mission-critical assets and ensure the continued operation of its customers IT infrastructures, with secure and reliable colocation and wholesale options. The Corporate & Other Business segment consists of the storage, safeguarding and electronic or physical deliveries of physical media of all types and digital content repository systems to house, distribute, and archive key media assets, primarily for entertainment and media industry clients. The company was founded by Herman Knaust in 1951 and is headquartered in Portsmouth, NH.

Iron Mountain Inc.

Iron Mountain is generating significant buzz after reporting record earnings and robust 2026 guidance, driven by accelerating data center expansion and continued strength in its physical storage business, while investors highlight consistent dividend growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuwellis Names Carisa Schultz CFO

(RTTNews) - Nuwellis, Inc. (NUWE), a medical technology company, on Friday announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2...

<ul class="summary-bullets"><li>Nuwellis did not disclose the value of the deal that is aimed at expanding the company’s portfolio into real-time renal diagnostics.</li><li>The company said that the transaction is expected to close upon the completion of customary closing conditions.</li><li>The Minneapolis-based company also announced a $5 million private placement and warrant inducement transaction priced at-the-market.</li></ul> Shares of Nuwellis Inc. (NUWE) slumped over 16% after-hours on Thursday after the company said that it has inked an agreement to acquire Israeli medical technology company Rendiatech.Nuwellis did not disclose the value of the deal, which is aimed at expanding the company’s portfolio into real-time renal diagnostics beyond therapeutic fluid management. Rendiatech is focused on automated kidney function monitoring.The company’s current portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions. &nbsp;<h2 class="st-heading-2">Upsides Of The Transaction</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229142/26106/en/Nuwellis-Enters-into-Definitive-Agreement-to-Acquire-Rendiatech-Advancing-Its-Cardiorenal-Portfolio-Strategy.html">said </a>that the transaction is expected to close upon the completion of customary closing conditions.Upon closing, Nuwellis will gain access to Rendiatech’s Clarity technology, allowing for expansion into advanced urine-based analytics and broader kidney function assessment, the company said, adding that the establishment of new sales channels is not expected to be needed to develop Rendiatech’s technology.“By entering into this transaction, we are positioning the company to extend our capabilities beyond therapeutic fluid removal and into real-time renal monitoring, which we believe is a natural and complementary evolution of our portfolio,” CEO John Erb said.Separately, the Minneapolis-based company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229143/26106/en/Nuwellis-Announces-5-Million-Private-Placement-and-Warrant-Inducement-Transaction-Priced-At-The-Market.html">announced</a> a $5 million private placement and warrant inducement transaction priced at-the-market. The transaction is expected to close on or about Jan. 30.The company did not detail the purposes for which the proceeds will be used. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NUWE stock stayed at ‘extremely bullish’ territory while message volume stayed at ‘extremely high’ levels.A Stocktwits user said that they are bullish on the acquisition until proven otherwise.<stembedurl>https://www.stocktwits.com/Nuckle_Head/message/643368696</stembedurl><a href="https://stocktwits.com/symbol/NUWE">NUWE stock</a> has dropped over 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-reportedly-considering-merger-with-xai-ahead-of-planned-ipo/cmyilBJR41B">Elon Musk’s SpaceX Reportedly Considering Merger With xAI Ahead Of Planned IPO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Nuwellis Stock Slips Over 26% After Hours On New Acquisition, $5M Placement Announcement

The company did not disclose the value of the acquisition, which is aimed at expanding the company’s portfolio into real-time renal diagnostics.

Equity

Nuwellis, Inc. Profit Declines In Q3

(RTTNews) - Nuwellis, Inc. (NUWE) announced earnings for third quarter that Dropped, from last year...

Nuwellis shares rose in after-hours trading after the company said it was granted a new U.S. Patent for innovations in blood filtering machine design and methods that improve fluid management accuracy during ultrafiltration therapy.At the close on Tuesday, <a href="https://stocktwits.com/symbol/NUWE">Nuwellis shares</a> dropped 11.7% to $6.9, but surged 31.3% to $9.05 in after-hours trading following news of the patent grant.The patent, titled “Extracorporeal Blood Filtering Machine and Methods”, addresses a critical source of error in continuous renal replacement therapy (CRRT) by factoring in actual fluid density, rather than assuming a standard value.&nbsp;Most current systems use 1 g/mL as&nbsp;the&nbsp;default, which can lead to miscalculations in fluid balance when actual densities differ.&nbsp;The new approach allows machines to adjust calculations based on input, measurement, or derived values, improving volumetric flow tracking and patient care.The company,&nbsp;based in Minneapolis with operations in Ireland,&nbsp;markets the Aquadex SmartFlow system for ultrafiltration and is&nbsp;The patent comes on the heels of two other major corporate developments in recent months.&nbsp;In June, Nuwellis raised $4.3 million through an underwritten public offering that included common stock and warrants. The company said the proceeds would go toward working capital, general corporate purposes, and potential acquisitions.In May, Nuwellis finalized a manufacturing agreement with KDI Precision Manufacturing, transferring assembly responsibilities for its Aquadex SmartFlow console and related products.&nbsp;The partnership&nbsp;aims to expand manufacturing capacity and enhance operational efficiency, with KDI also hiring current Nuwellis assembly employees to ensure a seamless transition.On Stocktwits, retail sentiment for Nuwellis was ‘extremely bullish’ by late Tuesday, improving from the ‘bullish’ mood a day ago, amid ‘extremely high’ message volume.One user said that a back-to-back spike within 24 hours typically signals that a larger move is underway.&nbsp;<stembedurl>https://stocktwits.com/Enjoiskating1216/message/621091545</stembedurl>Another expressed confidence in a major upside, suggesting the stock could revisit the $50 mark.<stembedurl>https://stocktwits.com/BestNwest/message/621099818</stembedurl>Nuwellis’ stock has declined 86.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nuwellis (NUWE) was granted a new U.S. Patent for innovations in blood filtering machine design. (Photo credit: Getty Images)

Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant

The patent for its blood filtering technology aims to improve fluid balance accuracy in CRRT by accounting for actual fluid density instead of relying on standard assumptions.

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon following its announcement that the Centers for Medicare and Medicaid Services (CMS) will significantly hike the reimbursement levels for its ultrafiltration therapy, lifting retail sentiment. Effective January 1, 2025, the reimbursement payment rate for the Minneapolis-based company’s Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase from $413 to $1,639 per day, a major step for the company’s outpatient therapy.&nbsp; Stocktwits users celebrated the move, suggesting the stock should go much higher following the news.&nbsp; &nbsp;<stembedurl>https://stocktwits.com/xpb199/message/591140624</stembedurl><stembedurl>https://stocktwits.com/Rampageusa/message/591116254</stembedurl> &nbsp;"This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” Nestor Jaramillo, President and CEO of Nuwellis, said in a statement. “It is well understood that providing care in an outpatient setting can be a better means to manage disease and prevent costly emergency hospitalizations.”&nbsp; The move will help expand the therapy’s reach to more patients on the sub-acute or chronic disease management program.Nuvellis plans to report its <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/nuwellis-shares-surge-following-preliminary-3q-results-c5fa917d">third-quarter</a> results and host its earnings conference call on November 11. The company said recently it is expecting to report revenue of $2.4 million, in line with the year-ago period.Nuwellis shares rallied over 106% today, but the stock is down roughly 88% year-to-date. Still, the stock is seeing a major jump in activity among retail investors and traders, with today’s symbol page views on Stocktwits hitting more than 25x their average over their one-month average.For updates and corrections, email newsroom@stocktwits.com

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon| Image source: Pixabay

Nuwellis Stock Spikes After Reimbursement Hike: Retail’s Upbeat

Effective January 1, 2025, the payment rate for its Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase 397% from $413 to $1,639 per day.

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Nuwellis Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

NUWE
Nuwellis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NUWE News

NUWENuwellis Inc